Background International research for acute myocardial infarction lacks comparisons of whole health systems. We assessed time trends for care and outcomes in Sweden and the UK.
Introduction
Recognition is growing of the need for comparative eff ectiveness research to improve the quality and outcomes of health care. International comparisons of cancer survival 1 and years of life lost to ischaemic heart disease 2 from 1990-2010 suggest that the performance of the UK health system needs to be improved. However, studies that simultaneously examine care and outcomes are lacking. The Institute of Medicine identifi ed healthcare delivery systems and cardio vascular care as among the highest priorities for comparative eff ectiveness research. 3 The effi cacy of treatments for acute myocardial infarction has been extensively studied in randomised trials, 4, 5 but uptake and use of these treatments vary within and between the UK (England and Wales) and Sweden. [6] [7] [8] [9] [10] A study in patients with ST-segment-elevation myocardial infarction (STEMI) in 12 European countries reported increasing use of primary percutaneous coronary intervention (PCI) but showed striking diff erences between countries. 11 Attributes of care systems, including organisational culture, care pathways, and programmes to improve quality, are not assessed in trials but might be associated with outcome. 12 30 -day mortality for acute myocardial infarction is an important indicator of hospital performance, and delivery of care has more immediate potential to improve outcomes than treatment innovations. 13 International comparisons of whole healthcare delivery systems, therefore, might yield important, actionable insights to guide development of policies and clinical practice. 14 International comparative eff ectiveness research for acute myocardial infarction has had three main limitations. First is a lack of comparison of whole health systems. Existing studies lack population coverage because they are based on selected samples of hospital patients reported in voluntary registries, [8] [9] [10] one-off surveys, 15 or trials 16 that are known to diff er from the national population in treatments and outcomes. 17 Second, international studies have compared only care 8 or outcomes 18 or have been restricted to patients with either STEMI [7] [8] [9] or non-STEMI. 10 Third, attempts have not been made to standardise the mortality of patients in one country by the casemix in another. As a result, there are few studies between health systems from which to set benchmark outcome goals.
A crucial feature of the health systems in Sweden and the UK is that they are the only two countries worldwide that have continuous national clinical registries for acute coronary syndrome with mandated participation for all hospitals. 19, 20 Comparison of these two countries is facilitated by the similarity of their health systems (universal, funded from taxation, and free at the point of use), proportion of gross domestic product spent on health, and national policy guidance provided for the evidence-based management of acute myocardial infarction. 21, 22 Diff erences are that Sweden has more rapid diff usion of some new technologies, 23 more complete use of evidence-based practice, 9 and a more established system for evaluating and reporting the quality and outcomes of care 24 than the UK.
In the absence of previous international comparisons, our objectives in this study were as follows: fi rst, to assess the validity of comparing data from the two nationwide clinical registries; second, to compare time trends for proportions of patients in receipt of eff ective interventions while in hospital and at discharge between 2004 and 2010; third, to compare crude and casemix-standardised 30-day mortality between the two countries and between clinically important subgroups; fourth to estimate time trends in casemix-standardised mortality and compare them between Sweden and the UK; and fi fth, to explore the contribution of clinical care to any diff erence in mortality.
Methods

Study population
All hospitals providing care for acute myocardial infarction in Sweden and the UK contribute data on consecutive patients to the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)/Register of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) and the UK Myocardial Ischaemia National Audit Project (MINAP), respectively. RIKS-HIA and MINAP comply with the Cardiology Audit and Registration Data Standards (for acute coronary syndrome in Europe. 7, 25, 26 We obtained data for all patients who were admitted to hospital because of acute myocardial infarction between Jan 1, 2004, and Dec 31, 2010 . For patients with multiple admissions we used the earliest record. Acute myocardial infarction diagnosis was based on guidelines from the European Society of Cardiology/American College of Cardiology/American Heart Association. 27 The study was approved by the MINAP Academic Group and the steering group of SWEDEHEART.
Casemix and treatment measures
The defi nitions of casemix, evidence-based hospital treatment, and discharge medications in SWEDEHEART/ RIKS-HIA and MINAP were compared (appendix pp 2-9). The 17 casemix characteristics were demographic factors (age, sex, year of admission), risk factors (smoking, history of diabetes mellitus, and hypertension), severity of acute myocardial infarction (troponin concentrations, systolic blood pressure at admission, heart rate at admission), history of heart failure, cardiac arrest at admission, history of cerebrovascular disease, or history of acute myocardial infarction, and previous procedures or use of medication (antiplatelet treatment with aspirin, clopidogrel, or both, PCI, coronary artery bypass graft surgery). Features of hospital treatment for STEMI were reperfusion therapy (primary PCI or fi brinolytic therapy before or during hospital stay), delay between symptom onset and primary PCI or fi brinolysis, coronary intervention other than primary PCI, intravenous glycoprotein IIb/IIIa inhibitors, and use of anticoagulants. Discharge medications assessed were antiplatelet therapy (aspirin, clopidogrel, or both), β blockers, angiotensinconverting-enzyme (ACE) inhibitors or angiotensinreceptor blockers (ARBs), and statins. Validation of SWEDEHEART/RIKS-HIA (each year a trained monitor compares data with a chart review in 30 randomly selected patients within each hospital) showed a 96·1% agreement. 20 Validation of MINAP data (compared with reaudit data, generated from each hospital annually by the re-entering of 20 data items on 20 randomly selected patients) showed a median agreement of 89·5%. 19 
Mortality
The primary clinical outcome was all-cause mortality within 30 days after hospital admission. National unique identifi ers were used to link patients with the National Death Registry in Sweden or the Offi ce for National Statistics in the UK. We accessed these registries to ascertain vital status or date of death at 30 days.
Statistical analysis
We compared troponin I and T concentrations, casemix, hospital treatment, and medication at discharge between Swedish and UK patients. Data are shown as proportion (95% CI) for categorical variables and mean (SD) or median (IQR) for continuous variables. diagnosis in the two registries, we compared the propensity of acute myocardial infarction diagnosis between UK and Sweden patients (appendix pp [12] [13] . Treatments for acute myocardial infarction were also compared by year of hospital admission.
We compared mortality outcomes with Kaplan-Meier analysis in clinically important subgroups (STEMI or non-STEMI, troponin concentration, systolic blood pressure at admission, heart rate at admission, sex, age, year of admission, diabetes status, and smoking), after casemix standardisation, and by propensity-score matching. In casemix standardisation, we modelled 30-day mortality for the two countries with the 17 casemix variables then applied the Sweden model to the UK acute myocardial infarction population to estimate the casemix-standardised relative risk of observed UK 30-day mortality for each study year and overall. In propensity matching, we estimated the propensity of being a STEMI patient and the propensity of being a non-STEMI patient in Sweden and the UK, according to logistic regression, and then matched patients on the basis of propensity scores (appendix pp [12] [13] [14] .
Casemix models incorporated a random eff ect for participant hospital. The extent of missing values was assessed and then managed by multiple imputation (appendix pp [16] [17] [18] [19] . Analyses were performed with SAS (version 9.3), R (version 2.9.2), and Matlab (version 7.14). This study is registered with ClinicalTrials.gov, number NCT01359033.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. S-CC had full access to all the data in the study. TJ and HH had fi nal responsibility for the decision to submit for publication.
Results
The study population was drawn from 86 hospitals in Sweden and 242 in the UK. 119 786 patients were eligible in Sweden and 391 077 in the UK (fi gure 1) and data on 30-day mortality were available for 119 786 (100%) and 390 951 (99·97%) of these, respectively.
Median concentrations (IQR) maximum troponin I and troponin T were similar in Sweden and the UK overall (table 1) and for STEMI and non-STEMI patients by year (appendix pp 10-11).
The proportion of patients with STEMI was lower in Sweden than in the UK (32% vs 40%). The distributions of age and sex were similar in the two countries (table 1) . Swedish patients had more favourable risk profi les than UK patients for some factors (eg, lower prevalence of current smoking and higher systolic blood pressure at admission), but worse risk profi les for other factors (eg, higher prevalence of diabetes, heart failure, and cerebrovascular disease). Previous use of antiplatelet and β-blocker therapy was greater in Sweden, but use of statins on admission was lower (table 1) .
Total reperfusion for STEMI was more common in the UK than in Sweden (77% vs 71%). Fibrinolysis was also more common in the UK (54% vs 12%), but primary PCI was notably more common in Sweden (59% vs 22%; table 1). The median delay from symptom onset to hospital admission was similar in the two countries. The median delay from symptom onset to primary PCI in STEMI patients was similar, but for fi brinolysis the delay was longer in Sweden (table 1) . Overall, coronary interventions (other than primary PCI) and use of intravenous glycoprotein IIb/IIIa agents were higher in Sweden than in the UK. For patients who survived to hospital discharge, those in Sweden were more likely than those in the UK to be prescribed dual antiplatelet therapy or β blockers, but less likely to be prescribed ACE inhibitors or ARBs and statins (table 1). In both countries the use of primary PCI to treat STEMI increased over time and use of fi brinolysis decreased (fi gure 2, appendix p 20). In 2004, almost all STEMI patients in the UK received fi brinolysis, but this decreased substantially over time and use of primary PCI reached the Swedish 2004 rate in 2009. Over time, the use of any antiplatelet medication at discharge was similar in the two countries. Use of dual antiplatelet therapy at discharge was initially low in the UK but increased over time and had exceeded that in Sweden by 2009 (appendix p 20). Use of β blockers at discharge was constantly higher in Sweden, whereas use of ACE inhibitors or ARBs and use of statins were higher in the UK (fi gure 2).
Cumulative 30-day mortality was higher in the UK than in Sweden (fi gure 3). When assessed according to troponin concentrations, acute infarct severity (heart rate and blood pressure at admission), age, sex, year of admission, smoking, and diabetes status, 30-day mortality in the UK remained consistently higher than that in Sweden (table 2). The strength and direction of casemixadjusted associations between 30-day mortality and age, year of admission, blood pressure, heart rate, diabetes status, history of cardiovascular disease, and previous revascularisation were similar in Sweden and the UK (appendix p 18). In-hospital mortality was also higher in the UK (8·8%, 8·7-8·9) than in Sweden (5·8%, 5·7-5·9).
In clinically important subgroups, in-hospital mortality was consistently higher in the UK than in Sweden (appendix p 21). After standardisation with the Swedish casemix model, UK mortality was lower than the unadjusted, crude estimates (appendix p 22). After standardisation, the forecast mean 30-day mortality between 2004 and 2010 was 7·7% (95% CI 7·3-8·2). If the same casemix was assumed in Sweden and the UK, the standardised mortality ratio was 1·37 (1·30-1·45), which corresponded to an estimated 11 263 (9620-12 827) more deaths in the UK between 2004 and 2010 than in Sweden. The greatest annual diff erence between countries in mortality was seen in 2004, when the standardised mortality ratio was 1·47 (1·38-1·58), but decreased signifi cantly over time to 1·20 (1·12-1·29) in 2010 (fi gure 4). The propensity-matched analyses gave similar fi ndings (appendix p 15). We explored the extent to which mortality diff erences between countries might be explained by diff erences in medical care, by casemix standardisation and treatment in hospital and also by estimating what might have diff ered if the UK had the same level of use of primary PCI and β blockers as Sweden from 2004 onwards, assuming treatment benefi ts reported in randomised clinical trials. If the level of use of primary PCI and β blockers had been the same in the UK as in Sweden, we estimate the standardised mortality ratio would have reduced from 1·37 to 1·31 (95% CI 1·30-1·33; appendix pp 22, 24) . When in-hospital treatments were included in addition to casemix, the standardised mortality ratio decreased from 1·37 to 1·21 (1·15-1·29 appendix pp 22-23).
Discussion
We found greater mortality among patients with acute myocardial infarction in the UK than similar patients in Sweden. The diff erences in the care and outcomes of acute myocardial infarction are a cause for concern. Uptake of eff ective treatments, especially primary PCI to treat STEMI and β blockers at discharge, was slower in the UK than in Sweden. The greater cumulative 30-day mortality in the UK was much improved after standardisation with the Swedish casemix. This approach suggests that more than 10 000 deaths at 30 days would have been prevented or delayed had UK patients experienced the care of their Swedish counterparts.
Several lines of evidence support the validity of comparing care and outcomes across these registries. First, by design we captured data on the whole system in both countries (all hospitals and consecutive patients) and have used common data defi nitions. That these data are comparable is supported by our fi nding that the associations between casemix variables and mortality were similar in the two countries. Second, the diagnosis of acute myocardial infarction was comparable, with troponin values and propensity to make a diagnosis being similar. Third, diff erences in 30-day mortality between countries were consistent within strata defi ned by troponin values and other clinically important subgroups.
The use of primary PCI to treat STEMI in the UK lagged behind that in Sweden; the rate in 2010 in the UK (53%) was similar to that in Sweden in 2005 (50%). Primary PCI was more eff ective than fi brinolysis in a meta-analysis, 28 and this fi nding was refl ected in guideline recommendations in the USA in 2004, 29 and in Europe in 2005. 30 The UK did not have a national policy for primary PCI until October, 2008, 31 which could explain the rapid increase in the use of this treatment from 2008 onwards, but it took until 2011-12 for rates to exceed 90%. 32 The use of evidence-based secondary prevention showed a mixed pattern, with statin therapy and ACE inhibitors or ARBs being more commonly prescribed in the UK than in Sweden, whereas use of β blockers at discharge was more common in Sweden. β blockers have been reported to be effi cacious for secondary prevention of acute myocardial infarction in randomised, controlled trials, and have been included in guideline recommendations for acute myocardial infarction in Europe 33 and the USA 34 since 1996, but their use was not recommended in the UK until 2001. 35 Our fi ndings suggest that these diff erences in clinical care contributed to international diff erences in patients' outcomes. The mortality gap between Sweden and the UK decreased over time, which is consistent with the narrowing gap between treatments. Application of Swedish rates of primary PCI and β blocker use to the UK population or inclusion of in-hospital treatments in the standardisation were associated separately with reduced diff erences in mortality between the two countries.
Other features of health care are not measured in these registries (eg, why particular patients do or do not receive particular types of care), and these features probably contribute to explaining the mortality gap. We show that improved understanding of selection processes in the two countries is needed (appendix p 23). Mortality might be aff ected by multiple unmeasured features of care, including doses, timing, adherence to drugs, diff erences in operator experience, shared and specialty care pathways, use of decision-support tools, and organisa tional culture. 12 In all countries, patients, payers and policymakers could ask how outcomes in their health systems compare with our results. Policy initiatives are required to identify, understand, and reduce gaps between treatment use and outcomes in diff erent health systems. We suggest that progress towards this goal is achievable because the narrowing of the gap between mortality in Sweden and the UK indicates that diff erences are reversible. Betweencountry comparisons of nationwide care and outcomes is a novel approach; most quality-outcome initiatives so far have been concentrated on within-country and withinsystem metrics. For Sweden our results highlight the value of quality of sustained, system-wide initiatives to improve quality, including the public reporting of outcomes at hospital level. For the UK our results suggest the usefulness of learning from systems that seem to be performing better. 1, 2 Our study has several limitations. First, we cannot exclude the possibility that unmeasured features of casemix contributed to the diff erences in mortality. However, standardisation, stratifi cation, and analysis of propensity scores all reported similar results, which supports an actual and signifi cant diff erence between countries. Our casemix model is as comprehensive as the registries allow and included 17 variables in demography, acute myocardial infarction severity, risk factor, comorbidity, and prehospital treatment. Second, we could not assess the care received by patients who died before reaching hospital, although we believe this is unlikely to explain the higher mortality in the UK because the time from symptom onset to admission was similar to that in 
Panel: Research in context
Systematic review
We searched Medline via PubMed with the medical subject headings "myocardial infarction", "Outcome Assessment (Health Care)", and "internationality" and identifi ed studies published in English from January, 1990 to September, 2013. Additional references from identifi ed studies, reviews, or relevant citations provided by experts were manually checked to supplement the literature searches. We identifi ed six closely relevant studies reporting substantial variation in the use and uptake of evidence-based medicine for care of acute myocardial infarction between countries. [8] [9] [10] [11] 15, 16 These studies, however, were based on selected samples of hospital patients in voluntary registries, 8-10 crosssectional surveys, 15 a clinical trial, 16 or with only ST-segment-elevation acute myocardial infarction (STEMI) [8] [9] 11 or non-STEMI. 10 One study reported important between-countries diff erences in acute myocardial infarction mortality 18 and the uptake of some evidencebased medicine. Our search revealed no previous studies comparing quality of care between two countries with nationwide coverage and taking into account heterogeneity in patients' casemix.
Interpretation
We found evidence of clinically important international diff erences in the uptake of eff ective treatments for and outcomes from AMI. 30-day mortality after AMI was higher among UK patients than among Swedish patients. Diff erences in mortality were not explained by diff erences in casemix, but were partly attributable to recorded diff erences in clinical care. International comparisons of care and outcome registries might yield important, actionable insights to guide health-care policy and clinical practice to improve the quality of health systems and prevent avoidable deaths from acute myocardial infarction.
Sweden and diff erences in mortality became apparent after the fi rst day in hospital. Third, the registries do not capture all patients admitted with acute myocardial infarction and, in the UK, missed patients are likely to be older and less likely to be under the care of a cardiologist than patients recorded in the registry. 36 Because the nationwide registries in Sweden have been established longer than in the UK, missed cases might be less frequent in Sweden, which suggests the actual diff erence in mortality could be wider. Fourth, the quality and completeness of data (in themselves markers of quality of care) might introduce bias in our casemix model. In sensitivity analyses, however, estimates for the associations between casemix variables and 30-day mortality based on complete case analysis verifi ed the results from multiple imputed data (appendix pp [18] [19] .
Our comparison of international outcomes suggests a novel research agenda (panel). 37 First, additional patientlevel health-care factors that are not measured might explain diff erences between countries. International harmonisation of detailed measures of quality of care in clinical registries, such as pathways of care, is needed. Second, at the national level, whether initiatives, such as national policies, fi nancial incentives, organisation, and leadership, aff ect the delivery of care is unclear. Third, outcomes should be compared with those in other countries, such as France, Hungary, Poland, and the USA, through assessment of national, albeit voluntary, registries. Fourth, with linkage to national electronic health records, there are opportunities to extend comparisons to include ambulatory care before and after admission for heart attack, non-fatal events, and longer-term outcomes. 38 We found clinically important diff erences in the care and outcomes of patients with acute myocardial infarction in Sweden and the UK. International comparisons of care and outcome registries might inform new research and policy initiatives to improve the quality of health systems.
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